Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025
Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC
.png?fit=crop&auto=format)
